{
    "Trade/Device Name(s)": [
        "ARCHITECT B.R.A.H.M.S PCT",
        "ARCHITECT B.R.A.H.M.S PCT Calibrators",
        "ARCHITECT B.R.A.H.M.S PCT Controls"
    ],
    "Submitter Information": "Fisher Diagnostics, A Division of Fisher Scientific Company, LLC (Thermo Fisher Scientific, Inc.)",
    "510(k) Number": "K170652",
    "Predicate Device Reference 510(k) Number(s)": [
        "K171338"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PRI",
        "PMT",
        "PTF",
        "JIT",
        "JJX"
    ],
    "Summary Letter Date": "March 1, 2017",
    "Summary Letter Received Date": "March 3, 2017",
    "Submission Date": "March 1, 2017",
    "Regulation Number(s)": [
        "21 CFR 866.3215",
        "21 CFR 862.1150",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis",
        "Calibrator, Secondary",
        "Quality Control Material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "microbiology"
    ],
    "Analyte(s)": [
        "Procalcitonin (PCT)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (Lithium Heparin and K2EDTA)"
    ],
    "Specimen Container(s)": [
        "K2EDTA tube",
        "Lithium Heparin tube",
        "Serum tube",
        "Serum Separator Tube (SST)"
    ],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT iSystem",
        "ARCHITECT i2000SR Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent microparticle immunoassay (CMIA)"
    ],
    "Methodologies": [
        "Quantitative immunoassay",
        "Chemiluminescence"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for ARCHITECT B.R.A.H.M.S PCT assay, calibrators, and controls for quantitative determination of procalcitonin in serum and plasma using chemiluminescent microparticle immunoassay on the ARCHITECT iSystem.",
    "Indications for Use Summary": "Used as an aid in risk assessment of critically ill ICU patients for progression to severe sepsis and septic shock, assessment of 28-day mortality risk, antibiotic therapy decision for lower respiratory tract infections, and antibiotic discontinuation in sepsis; calibrators and controls for use with ARCHITECT iSystem.",
    "fda_folder": "Microbiology"
}